**Introduction**

- **Mechanism of action**
  - LP-184 acts via different mechanisms, targeting tumor cells and normal tissue.
  - It is a novel prodrug that undergoes active metabolite formation in the tumor microenvironment.
  - Active metabolite interferes with protein synthesis and cell proliferation.

- **Clinical trial settings**
  - Phase II clinical trial to assess safety and efficacy.
  - Patients with recurrent glioblastoma (GBM).

**Key findings and future directions**

- **Key findings**
  - LP-184 shows promising activity in glioblastoma.
  - Improved outcomes compared to standard therapy.

- **Future directions**
  - Ongoing clinical trials to further evaluate efficacy.
  - Combination therapies to enhance treatment results.

**References**

1. The Kennedy Krieger Institute, 707 N. Broadway, Baltimore MD 21205
2. Lantern Pharma, 1020 McKinney Ave, 7th Floor, Dallas TX 75235
3. Johns Hopkins School of Medicine, 600 N. Wolfe St, Baltimore, MD 21205